Education
About Us
Working with TipRanks
Follow Us
Savara (SVRA)
NASDAQ:SVRA
SVRA Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.26 - $5.34
Previous CloseN/A
Volume189.20K
Average Volume (3M)1.11M
Market Cap
$475.38M
Enterprise Value$705.50M
Total Cash (Recent Filing)$24.30M
Total Debt (Recent Filing)$24.57M
Price to Earnings (P/E)―
Beta1.30
Next Earnings
May 08, 2025EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.44
Shares Outstanding171,618,940
10 Day Avg. Volume1,739,138
30 Day Avg. Volume1,111,135
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-5.30
P/FCF Ratio0.00
Enterprise Value/Market Cap1.48
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-15.94
Enterprise Value/Ebitda-7.95
Forecast
1Y Price Target
$9.00Price Target Upside233.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Savara News
PremiumCompany Announcements
Savara Secures $200 Million Loan Agreement with Hercules
PremiumCompany Announcements
Savara Sets 2025 Executive Bonus Targets
PremiumCompany Announcements
Savara Highlights MOLBREEVI’s Potential in Rare Disease Market
---
Bulls Say, Bears Say
Bulls Say
Financial PositionSVRA had $219M in cash, providing a financial runway through 2Q27, and the debt deal with Hercules gives the company breathing room for the early launch.
Market PotentialSavara and its drug Molbreevi have strong clinical data, meet a major unmet need, and face no competition, making them an attractive biotech opportunity.
Regulatory ApprovalSavara is requesting Priority Review, which is likely given Molbreevi’s Breakthrough Therapy designation, impressive Phase 3 data, and high unmet need in aPAP.
Bears Say
Commercialization RisksThe commercial opportunity in aPAP is underappreciated, with a diagnosed U.S. population greater than literature estimates and an expectation for premium rare disease pricing.
Regulatory RisksRisks include regulatory approval, commercializing Molbreevi in the US, and the need for additional financing.
Supply Chain ConcernsEven in the unlikely scenario of a setback on FDA inspections, SVRA could switch to Fujifilm as a supplier, suggesting FDA approval is a matter of time.
---
Ownership Overview
12.60% Insiders
10.66% Mutual Funds
0.02% Other Institutional Investors
66.88% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
SVRA FAQ
What was Savara’s price range in the past 12 months?
Savara lowest stock price was $2.25 and its highest was $5.34 in the past 12 months.
What is Savara’s market cap?
Savara’s market cap is $475.38M.
When is Savara’s upcoming earnings report date?
Savara’s upcoming earnings report date is May 08, 2025 which is in 41 days.
How were Savara’s earnings last quarter?
Currently, no data Available
Is Savara overvalued?
According to Wall Street analysts Savara’s price is currently Undervalued.
Does Savara pay dividends?
Savara does not currently pay dividends.
What is Savara’s EPS estimate?
Savara’s EPS estimate is -0.11.
How many shares outstanding does Savara have?
Savara has 171,618,940 shares outstanding.
What happened to Savara’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Savara?
Currently, no hedge funds are holding shares in SVRA
---
Savara Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$9.00 (233.33% Upside)
$9.00 (233.33% Upside)
Blogger Sentiment
Bullish
SVRA Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 3.8M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $665.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.3%
Last 30 Days ▼ 5.6%
Last 30 Days ▼ 5.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-45.01%
12-Months-Change
Fundamentals
Return on Equity
-47.95%
Trailing 12-Months
Asset Growth
31.17%
Trailing 12-Months
Company Description
Savara
Savara Inc. is a pharmaceutical company focused on the development and commercialization of novel therapies for rare respiratory diseases. The company is dedicated to addressing unmet medical needs in this specialized sector, with its core product being Molgradex, an inhaled formulation of recombinant human GM-CSF, aimed at treating autoimmune pulmonary alveolar proteinosis (aPAP).
---
SVRA Stock 12 Month Forecast
Average Price Target
$9.00
▲(233.33% Upside)
Technical Analysis
Best Analysts Covering SVRA
1 Year
1 Year Success Rate
5/10 ratings generated profit
1 Year Average Return
+11.38%
assigned a buy rating 6 months ago
Copying Yasmeen Rahimi's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +11.38% per trade.
---